PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

FDA Push for TRF Therapies Will ‘Disrupt Pain Market’

Global Parkinson’s Disease Market to Drop by $0.5 Billion by 2019

GSK Doubles Down on COPD and Asthma

Advertisement
special feature
Best of the Blog: Pharm Exec’s 10 Most Read Stories of 2013
Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. Looking back on 2013, here are the 10 most-read stories published on PharmExec’s blog during the year, in case you missed them
... /Read more/
Social Media
Pharm Exec Global Digest Social Media Special
In the latest issue of Pharm Exec Global Digest: Has Pharma Finally ‘Got’ Social Media? — Five Ways Advanced Social Intelligence Can Guide Pharma Strategy ­­— Preparing for Crisis in an ‘Always On’ Digital Word — and more
... /Read more/
Calendar
/ January 28–29, 2014: 11th Annual Pharmaceutical Compliance Congress/
Washington, DC.
/ January 28–29, 2014: Real World Evidence/
Philadelphia, PA.
/ GSK Doubles Down on COPD and Asthma/
Baltimore, MD.
Employment survey
Pharma Industry Optimism Outweighs Concerns for Job Security
Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed muted optimism despite stagnant employment options in Pharmaceutical Technology’s latest employment survey
... /Read more/
Global
Europe’s New Clinical Trial Rules: Questions Remains on Data Transparency
In the latest issue of Pharm Exec Global Digest: Has Pharma Finally ‘Got’ Social Media? — Five Ways Advanced Social Intelligence Can Guide Pharma Strategy ­­— Preparing for Crisis in an ‘Always On’ Digital Word — and more
... /Read more/
Industry update
//Agilis Biotherapeutics (New York, NY) named George S. Zorich as the company’s new Chief Executive Officer.//ImmunoGen, Inc. (Waltham, MA) appointed David Johnston as Chief Financial Officer.//Halozyme Therapeutics, Inc. (San Diego, CA) announced that Helen Torley will be joining as President and Chief Executive Officer on January 6.//Wendell Wierenga, Ph.D, was appointed to the Board of Directors of Ocera Therapeutics, Inc. (Palo Alto, CA).//
advertise with us / print subscribe / digital subscribe / visit pharmexec.com